NASDAQ$TPST
Tempest Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Tempest Therapeutics reported Q3 2025, revenue of $500K, net loss of $28M.
For Q3 2025, Tempest Therapeutics reported revenue of $500K, a net loss of $28M. Management discusses segment performance, capital allocation, and sector risks in the quarterly filing.
- Revenue $500K.
- Net loss $28M.
- Tempest Therapeutics MD&A covers liquidity, credit, and operating priorities.
Headline financials
Revenue & EPS history
Tempest · Revenue · Quarterly
$500K
Forward guidance
Clinical or pre-revenue biotech outlook centers on trial milestones, partnerships, and cash runway.
Tailwinds
- Pipeline milestones and collaboration optionality.
- Cash and marketable securities fund operations.
Headwinds
- Trial failure or delay risk.
- Dilution from future financings.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
-2.1%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-10.2%
Avg return
30 days after
34%
12 / 35 earnings
Positive
+15.8%
Q2 2022
Best reaction
-41.3%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.2% | +4.5% | -36.2% | |
| Q3 2025 | -3.2% | -3.3% | -68.6% | |
| Q2 2025 | +10.0% | +31.5% | +33.7% | |
| Q1 2025 | -2.6% | -8.2% | +0.7% | |
| Q4 2024 | +5.9% | -9.5% | -28.9% | |
| Q3 2024 | -11.5% | -19.1% | -24.1% | |
| Q2 2024 | -16.8% | -21.4% | -11.4% | |
| Q1 2024 | -5.5% | -2.0% | -10.4% | |
| Q4 2023 | -3.1% | -5.9% | -18.1% | |
| Q3 2023 | +6.1% | +11.7% | +3.6% | |
| Q2 2023 | +7.2% | +13.5% | -29.1% | |
| Q1 2023 | +3.4% | +6.3% | -42.0% | |
| Q4 2022 | +10.2% | +8.1% | +80.3% | |
| Q3 2022 | -12.1% | -11.5% | -14.0% | |
| Q2 2022 | +15.8% | +18.2% | +5.1% | |
| Q1 2022 | +5.9% | +12.9% | -2.2% | |
| Q4 2021 | -3.6% | -18.8% | -12.4% | |
| Q3 2021 | -2.5% | -7.8% | -35.5% | |
| Q2 2021 | -0.1% | -6.3% | +6.3% | |
| Q1 2021 | -0.8% | -1.6% | -10.2% | |
| Q4 2020 | -41.3% | -41.7% | -46.3% | |
| Q3 2020 | -1.3% | -1.3% | +28.2% | |
| Q2 2020 | -2.6% | -3.6% | -17.7% | |
| Q1 2020 | -4.7% | +0.0% | +32.0% | |
| Q3 2019 | -2.7% | +1.2% | -21.1% | |
| Q2 2019 | -0.5% | -7.4% | -23.2% | |
| Q1 2019 | +2.6% | +0.9% | -21.2% | |
| Q3 2018 | -5.2% | -13.0% | -10.0% | |
| Q2 2018 | -14.4% | -8.9% | -15.6% | |
| Q1 2018 | +0.7% | +0.7% | -4.7% | |
| Q3 2017 | -4.6% | -2.9% | -0.7% | |
| Q2 2017 | +3.1% | -2.5% | -12.3% | |
| Q1 2017 | -0.4% | -1.8% | -8.1% | |
| Q3 2016 | -6.8% | -31.6% | -35.4% | |
| Q2 2016 | -0.5% | +11.2% | +12.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro